Royalty Pharma plc is the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences sector. The company acquires royalties entitling it to payments based on net sales of approved therapies and development-stage product candidates, partnering with innovators from academic institutions, research hospitals, nonprofits, small and mid-cap biotechnology firms, and major global pharmaceutical companies. Its extensive portfolio encompasses royalties on more than 35 commercial products addressing conditions such as cystic fibrosis (e.g., Vertex's Trikafta and Kalydeco), multiple sclerosis (e.g., Biogen's Tysabri and Spinraza), blood cancers (e.g., Imbruvica from AbbVie and Johnson & Johnson), prostate cancer (e.g., Xtandi from Astellas and Pfizer), ATTR amyloidosis (e.g., Alnylam's Amvuttra), and schizophrenia (e.g., Bristol Myers Squibb's Cobenfy), alongside over 20 pipeline assets targeting vitiligo, Hunter syndrome, lupus, hereditary angioedema, and cardiovascular disease. Royalty Pharma plc provides tailored non-dilutive funding solutions to support late-stage clinical trials and product launches, holding a dominant position with significant global market share in biopharma royalty transactions. Founded in 1996 and headquartered in New York, NY, it operates at the intersection of science, medicine, and investing to accelerate bio-innovation.